Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds

Assay and Drug Development Technologies

Volumn 2, Issue 5, 2004, Pages 497-506

  Tao, Huimin ^a   Santa Ana, David ^a   Guia, António ^a   Huang, Mingxian ^a   Ligutti, Joseph ^a,b   Walker, George ^a   Sithiphong, Khachonesine ^a   Chan, Florence ^a   Guoliang, Tao ^a   Zozulya, Zoya ^a   Saya, Steve ^a   Phimmachack, Rick ^a   Sie, Charles ^a   Yuan, Julian ^a   Wu, Lei ^a   Xu, Jia ^a   Ghetti, Andrea ^a  

^a AVIVA Biosciences Corporation   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ASTEMIZOLE; BEPRIDIL; CISAPRIDE; DIPHENHYDRAMINE; HALOPERIDOL; PIMOZIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL HERG; QUINIDINE; TERFENADINE; THIORIDAZINE; VERAPAMIL;

ANIMAL CELL; ARTICLE; AUTOMATION; CONTROLLED STUDY; DRUG SCREENING; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; MICROPIPETTE; NONHUMAN; PROTEIN FUNCTION; QT PROLONGATION; RELIABILITY; TORSADE DES POINTES; VOLTAGE CLAMP;

AMIODARONE; ANIMALS; CATION TRANSPORT PROTEINS; CHO CELLS; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, VOLTAGE-GATED;

EID: 10244245061     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2004.2.497     Document Type: Article

References (12)

1. Fermini B, Fossa A: The impact of drug-induced QT interval prolongation on drug discovery and development. Nat Rev Drug Discov 2003;2:439-447.
2. Redfern WS, Carlsson AS, Davis AS, Lynch WG, MacKenzie I, Palenthorpe S, Siegl PKS, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG: Relationship between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
3. Keating MT, Sanguinetti MC: Molecular and cellular mechanisms of cardiac arrhythmias. Cell 2001;104:569-580.
4. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-1022.
5. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC: A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci U S A 2000;97:12329-12333.
6. + channel block. J Biol Chem 2002;277:23587-23595.
7. + channel and its structural implications. Nature 2000;403:321-325.
8. Xu J, Wang X, Ensign B, Li M, Wu L, Guia A, Xu J: Ion-channel assay technologies: quo vadis? Drug Discov Today 2001;6:1278-1287.
9. Woosley RL, Chen Y, Freiman JP, Gillis RA: Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269: 1532-1536.
10. Xu J, Guia A, Rothwarf D, Huang M, Sithiphong K, Ouang J, Tao G, Xiaobo W, Wu L: A benchmark study with SealChip™ planar patch-clamp technology. Assay Drug Dev Technol 2003;1:675-684.
11. Sakmann B, Neher E: Single-Channel Recording, 2nd ed. Kluwer Academic Publishers, Dordrecht, the Netherlands, 1995.
12. Wang J, Della Penna K, Wang H, Karczewski J, Connolly TM, Koblan KS, Bennett PB, Salata JJ: Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol Heart Circ Physiol 2003;284: H256-H267.